|CRDAMC Homepage | CRDAMC Library Phone #: (254) 288-8366 | CRDAMC Library Fax #: (254) 288-8368|
Lewy Body Disease
(Lewy Body Dementia; Dementia with Lewy Bodies)
by Krisha McCoy, MS
Lewy body disease is a type of dementia. Dementia is the progressive loss of memory and various other mental functions, including the ability to learn, reason, and judge.
Lewy body disease is associated with the buildup of Lewy bodies in regions of the brain. These are abnormal protein deposits inside cells that play a role in certain aspects of memory, visual processing, and motor control. It is not clear exactly what causes the buildup of Lewy bodies in the brain.
Risk Factors TOP
Lewy body disease is more common in men, and in people over 50 years old. It is also more common in people with a family history of Lewy body disease, Parkinson disease, or other dementias.
The disease is linked to:
Lewy body disease is characterized by:
You will be asked about your symptoms and medical history. A physical exam will be done. A doctor can do tests to narrow the cause of dementia. Other tests may include:
The only way to confirm Lewy body disease is through an autopsy after death.
While there is no cure for Lewy body disease, there are treatments that can control the symptoms. Talk with your doctor about the best treatment plan for you. Treatment options include:
These medications may be used to help with the symptoms:
If you have Lewy body disease, you may be sensitive to medications called neuroleptics. You may have adverse events with these medications.
There are no current guidelines to prevent Lewy body disease.
Lewy Body Dementia Association
National Institute of Neurological Disorders and Stroke
Canadian Stroke Network
An introduction to Lewy body dementia. Lewy Body Disease Association website. Available at:
...(Click grey area to select URL)
Accessed October 2, 2017.
Ballard CG, Chalmers KA, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007;68(20):1726-1729.
Bouchard RW. Diagnostic criteria of dementia. Can J Neurol Sci. 2007;34:(Suppl 1)S11-S18.
Camicioli R, Gauthier S. Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. Can J Neurol Sci. 2007;34:(Suppl 1)S109-S117.
Chou KL, Borek LL, et al. The management of psychosis in movement disorder patients. Expert Opin Pharmacother. 2007;8(7):935-943.
Dementia with Lewy bodies. EBSCO DynaMed Plus website. Available at: http://www.dynamed.... Updated May 3, 2017. Accessed October 2, 2017.
Emre M, Tsolaki M, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewey bodies: a randomised, double-blind, placebo controlled trial. Lancet Neurol. 2010;9(10):969-77.
Goldmann Gross R, Siderowf A. Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies: a spectrum of disease. Neurosignals. 2008;16(1):24-34.
Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol. 2009;256(Suppl 3):270-279.
Kemp PM, Hoffmann SA, et al. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun. 2007;28(6):451-456.
Meeus B, Theuns J, et al. The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol. 2012;69(9):1113-8.
NINDS dementia with Lewy bodies information page. National Institute of Neurological Disorders and Stroke website. Available at: https://www.ninds.nih.gov/Disorders/All-Disorders/Dementia-Lewy-Bodies-Information-Page. Accessed October 2, 2017.
Tarawneh R, Galvin JE. Distinguishing Lewy body dementias from Alzheimer’s disease. Expert Review of Neurotherapeautics. 2007;7(11):1499-1516.
Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491-1498.
9/3/2014 DynaMed Plus Systematic Literature Surveillance. Available at: http://www.dynamed.com/topics/dmp~AN~T115618/Dementia-evaluation: Wippold FJ, Brown DC, Broderick DF, et al. American College of Radiology (ACR) Appropriateness Criteria for dementia and movement disorders. Available at:
...(Click grey area to select URL)
Updated 2014. Accessed September 3, 2014.
Last reviewed September 2017 by EBSCO Medical Review Board Rimas Lukas, MD
Last Updated: 9/15/2016
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at email@example.com. Our Health Library Support team will respond to your email request within 2 business days.